1. Li HH, et al. J Allergy Clin Immunol Pract 2015; 3(3):417-423
  2. Based on a post-hoc analysis of pooled data from the randomized controlled trial and open-label extension phases of 2 studies involving 127 patients aged ≥13 years treated with RUCONEST® 50 U/kg for acute attacks of HAE. Data for 72 hours available for 68 of 127 patients. Please see Bernstein, J. A., et al. “Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks.” Ann.Allergy Asthma Immunol. 118.4 (2017): 452-55.
  3. Farrell, C., et al. “Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.” Br.J.Clin.Pharmacol. 76.6 (2013): 897-907.
  4. Moldovan, D., J. A. Bernstein, and M. Cicardi. “Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency.” Immunotherapy. 7.7 (2015): 739-52.
  5. van Veen, H. A., et al. “Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits.” J.Biotechnol. 162.2-3 (2012): 319-26.
  6. Feussner, A., et al. “Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema.” Transfusion. 54.10 (2014): 2566-73.
  7. Ruconest SmPC – – accessed 140920
  8. Riedl, M. A., et al. “Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.” Ann.Allergy Asthma Immunol. 112.2 (2014): 163-69.
  9. Hack CE, et al. Eur J Allergy Clin Immunol 2012; 67(1):123-130
  10. Reshef, A., et al. “Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.” Pediatr Allergy Immunol. 2019;30(5):562-568.